AbbVie Inc. Net Income
AbbVie Inc. (ABBV) reported Net Income of $3.61 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-03
- AbbVie Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $3.61B, a 285.18% increase year-over-year.
- AbbVie Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $695.00M, a 45.96% decline year-over-year.
- AbbVie Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.82B.
- AbbVie Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $186.00M, a 88.08% decline year-over-year.
- AbbVie Inc. net income (loss) attributable to parent for fiscal 2025 was $4.23B, a 1.22% decline from fiscal 2024.
- AbbVie Inc. net income (loss) attributable to parent for fiscal 2024 was $4.28B, a 12.03% decline from fiscal 2023.
- AbbVie Inc. net income (loss) attributable to parent for fiscal 2023 was $4.86B, a 58.91% decline from fiscal 2022.
- AbbVie Inc. net income (loss) attributable to parent for fiscal 2022 was $11.84B, a 2.55% increase from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.61B 10-Q · filed 2026-08-03 | $4.31B 10-Q · filed 2026-08-03 | $6.12B derived: sum of 3 quarters · filed 2026-08-03 | $6.31B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $695.00M 10-Q · filed 2026-05-08 | $2.51B derived: sum of 2 quarters · filed 2026-05-08 | $2.70B derived: sum of 3 quarters · filed 2026-05-08 | $3.63B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $1.82B 10-K · filed 2026-02-20 | $2.00B derived: sum of 2 quarters · filed 2026-02-20 | $2.94B derived: sum of 3 quarters · filed 2026-08-03 | $4.23B 10-K · filed 2026-02-20 |
| 2025-09-30 | $186.00M 10-Q · filed 2025-11-04 | $1.12B derived: sum of 2 quarters · filed 2026-08-03 | $2.41B 10-Q · filed 2025-11-04 | $2.39B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $938.00M 10-Q · filed 2026-08-03 | $2.22B 10-Q · filed 2026-08-03 | $2.20B derived: sum of 3 quarters · filed 2026-08-03 | $3.76B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.29B 10-Q · filed 2026-05-08 | $1.26B derived: sum of 2 quarters · filed 2026-05-08 | $2.83B derived: sum of 3 quarters · filed 2026-05-08 | $4.20B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$22.00M 10-K · filed 2025-02-14 | $1.54B derived: sum of 2 quarters · filed 2025-11-04 | $2.91B derived: sum of 3 quarters · filed 2025-11-04 | $4.28B 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.56B 10-Q · filed 2025-11-04 | $2.93B derived: sum of 2 quarters · filed 2025-11-04 | $4.30B 10-Q · filed 2025-11-04 | $5.12B derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.37B 10-Q · filed 2025-08-04 | $2.74B 10-Q · filed 2025-08-04 | $3.56B derived: sum of 3 quarters · filed 2025-08-04 | $5.34B derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $1.37B 10-Q · filed 2025-05-09 | $2.19B derived: sum of 2 quarters · filed 2025-05-09 | $3.97B derived: sum of 3 quarters · filed 2025-05-09 | $5.99B derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $822.00M 10-K · filed 2024-02-20 | $2.60B derived: sum of 2 quarters · filed 2024-11-04 | $4.62B derived: sum of 3 quarters · filed 2024-11-04 | $4.86B 10-K · filed 2026-02-20 |
| 2023-09-30 | $1.78B 10-Q · filed 2024-11-04 | $3.80B derived: sum of 2 quarters · filed 2024-11-04 | $4.04B 10-Q · filed 2024-11-04 | $6.51B derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $2.02B 10-Q · filed 2024-08-07 | $2.26B 10-Q · filed 2024-08-07 | $4.74B derived: sum of 3 quarters · filed 2024-08-07 | $8.69B derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $239.00M 10-Q · filed 2024-05-03 | $2.71B derived: sum of 2 quarters · filed 2024-05-03 | $6.66B derived: sum of 3 quarters · filed 2024-05-03 | $7.58B derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $2.47B 10-K · filed 2023-02-17 | $6.42B derived: sum of 2 quarters · filed 2023-11-06 | $7.35B derived: sum of 3 quarters · filed 2023-11-06 | $11.84B 10-K · filed 2025-02-14 |
| 2022-09-30 | $3.95B 10-Q · filed 2023-11-06 | $4.87B derived: sum of 2 quarters · filed 2023-11-06 | $9.36B 10-Q · filed 2023-11-06 | $13.41B derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $924.00M 10-Q · filed 2023-08-07 | $5.41B 10-Q · filed 2023-08-07 | $9.46B derived: sum of 3 quarters · filed 2023-08-07 | $12.64B derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $4.49B 10-Q · filed 2023-05-05 | $8.53B derived: sum of 2 quarters · filed 2023-05-05 | $11.71B derived: sum of 3 quarters · filed 2023-05-05 | $12.48B derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $4.04B 10-K · filed 2022-02-18 | $7.22B derived: sum of 2 quarters · filed 2022-11-04 | $7.99B derived: sum of 3 quarters · filed 2022-11-04 | $11.54B 10-K · filed 2024-02-20 |
| 2021-09-30 | $3.18B 10-Q · filed 2022-11-04 | $3.94B derived: sum of 2 quarters · filed 2022-11-04 | $7.50B 10-Q · filed 2022-11-04 | $7.53B derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $766.00M 10-Q · filed 2022-08-04 | $4.32B 10-Q · filed 2022-08-04 | $4.36B derived: sum of 3 quarters · filed 2022-08-04 | $6.66B derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.55B 10-Q · filed 2022-05-06 | $3.59B derived: sum of 2 quarters · filed 2022-05-06 | $5.90B derived: sum of 3 quarters · filed 2022-05-06 | $5.16B derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $36.00M 10-K · filed 2021-02-19 | $2.34B derived: sum of 2 quarters · filed 2021-11-02 | $1.61B derived: sum of 3 quarters · filed 2021-11-02 | $4.62B 10-K · filed 2023-02-17 |
| 2020-09-30 | $2.31B 10-Q · filed 2021-11-02 | $1.57B derived: sum of 2 quarters · filed 2021-11-02 | $4.58B 10-Q · filed 2021-11-02 | $7.38B derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | -$738.00M 10-Q · filed 2021-08-02 | $2.27B 10-Q · filed 2021-08-02 | $5.07B derived: sum of 3 quarters · filed 2021-08-02 | $6.96B derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | $3.01B 10-Q · filed 2021-05-07 | $5.81B derived: sum of 2 quarters · filed 2021-05-07 | $7.70B derived: sum of 3 quarters · filed 2021-05-07 | $8.44B derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $2.80B 10-K · filed 2020-02-21 | $4.68B derived: sum of 2 quarters · filed 2020-11-04 | $5.43B derived: sum of 3 quarters · filed 2020-11-04 | $7.88B 10-K · filed 2022-02-18 |
| 2019-09-30 | $1.88B 10-Q · filed 2020-11-04 | $2.63B derived: sum of 2 quarters · filed 2020-11-04 | $5.08B 10-Q · filed 2020-11-04 | $3.25B derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $741.00M 10-Q · filed 2020-08-04 | $3.20B 10-Q · filed 2020-08-04 | $1.37B derived: sum of 3 quarters · filed 2020-08-04 | $4.12B derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | $2.46B 10-Q · filed 2020-05-08 | $630.00M derived: sum of 2 quarters · filed 2020-05-08 | $3.38B derived: sum of 3 quarters · filed 2020-05-08 | $5.36B derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | -$1.83B 10-K · filed 2020-02-21 | $921.00M derived: sum of 2 quarters · filed 2020-02-21 | $2.90B derived: sum of 3 quarters · filed 2020-02-21 | $5.69B 10-K · filed 2021-02-19 |
| 2018-09-30 | $2.75B 10-K · filed 2020-02-21 | $4.73B derived: sum of 2 quarters · filed 2020-02-21 | $7.51B 10-Q · filed 2019-11-06 | $7.57B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $1.98B 10-K · filed 2020-02-21 | $4.77B 10-Q · filed 2019-08-05 | $4.82B derived: sum of 3 quarters · filed 2020-02-21 | $6.45B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $2.78B 10-K · filed 2020-02-21 | $2.83B derived: sum of 2 quarters · filed 2020-02-21 | $4.47B derived: sum of 3 quarters · filed 2020-02-21 | $6.38B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $52.00M 10-K · filed 2019-02-27 | $1.68B derived: sum of 2 quarters · filed 2019-02-27 | $3.60B derived: sum of 3 quarters · filed 2019-02-27 | $5.31B 10-K · filed 2020-02-21 |
| 2017-09-30 | $1.63B 10-K · filed 2019-02-27 | $3.55B derived: sum of 2 quarters · filed 2019-02-27 | $5.26B 10-Q · filed 2018-11-07 | $6.65B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $1.92B 10-K · filed 2019-02-27 | $3.63B 10-Q · filed 2018-08-07 | $5.02B derived: sum of 3 quarters · filed 2019-02-27 | $6.62B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $1.71B 10-K · filed 2019-02-27 | $3.10B derived: sum of 2 quarters · filed 2019-02-27 | $4.70B derived: sum of 3 quarters · filed 2019-02-27 | $6.31B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $1.39B 10-K · filed 2018-02-16 | $2.99B derived: sum of 2 quarters · filed 2018-02-16 | $4.60B derived: sum of 3 quarters · filed 2018-02-16 | $5.95B 10-K · filed 2019-02-27 |
| 2016-09-30 | $1.60B 10-K · filed 2018-02-16 | $3.21B derived: sum of 2 quarters · filed 2018-02-16 | $4.56B 10-Q · filed 2017-11-07 | $6.08B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $1.61B 10-K · filed 2018-02-16 | $2.96B 10-Q · filed 2017-08-07 | $4.48B derived: sum of 3 quarters · filed 2018-02-16 | $5.72B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $1.35B 10-K · filed 2018-02-16 | $2.87B derived: sum of 2 quarters · filed 2018-02-16 | $4.11B derived: sum of 3 quarters · filed 2018-02-16 | $5.48B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $1.52B 10-K · filed 2017-02-17 | $2.76B derived: sum of 2 quarters · filed 2017-02-17 | $4.12B derived: sum of 3 quarters · filed 2017-02-17 | $5.14B 10-K · filed 2018-02-16 |
| 2015-09-30 | $1.24B 10-K · filed 2017-02-17 | $2.60B derived: sum of 2 quarters · filed 2017-02-17 | $3.63B 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $1.37B 10-K · filed 2017-02-17 | $2.39B derived: sum of 2 quarters · filed 2017-02-17 | ||
| 2015-03-31 | $1.02B 10-K · filed 2017-02-17 | |||
| 2014-12-31 | $1.77B 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |